Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A two-step centrifugal microfluidic platform for semi-automated IGRA detection of tuberculosis based on chemiluminescence.

The Analyst·2026
Same author

Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.

Viruses·2026
Same author

Molecular basis of host ATP level modulation by actin-dependent secreted bacterial ATPase and its metaeffector.

Nature communications·2026
Same author

Structural basis and immunogenic efficacy of porcine circovirus type 3 virus-like particle.

Nature communications·2026
Same author

Sexual dimorphism of COVID-19 inspires drug repositioning and host-targeting immunotherapy for viral pneumonia.

Signal transduction and targeted therapy·2026
Same author

An All-in-One Microfluidic Platform for POCT-Ready Nucleic Acid Extraction from Heterogeneous Clinical Samples.

Analytical chemistry·2026

Related Experiment Video

Updated: Jul 3, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.2K

Progress and Challenges to Hepatitis E Vaccine Development and Deployment.

Xingcheng Huang1,2, Jiaoxi Lu1,2, Mengjun Liao1,2

  • 1State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen 361000, China.

Vaccines
|July 27, 2024
PubMed
Summary

Hepatitis E virus (HEV) infection causes significant illness and epidemics. The HEV 239 vaccine shows sustained efficacy for 10 years, offering a promising prevention strategy against this liver disease.

Keywords:
HEVclinical trialhepatitis Eoutbreaksprogressvaccine

More Related Videos

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

6.9K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.7K

Related Experiment Videos

Last Updated: Jul 3, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.2K
Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

6.9K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.7K

Area of Science:

  • Hepatology
  • Vaccinology
  • Infectious Diseases

Background:

  • Hepatitis E is a major cause of acute hepatitis with high mortality, especially in pregnant women and those with chronic liver disease.
  • Fecal-oral transmission facilitates large-scale epidemics of Hepatitis E virus (HEV).
  • No specific antiviral treatments for Hepatitis E are currently approved.

Purpose of the Study:

  • To review the progress and challenges in the development of Hepatitis E vaccines.
  • To highlight the efficacy and safety of the licensed HEV 239 vaccine.

Main Methods:

  • Review of clinical trial data for the HEV 239 vaccine.
  • Analysis of long-term efficacy and safety data from Phase III trials.
  • Summary of global HEV vaccine development landscape.

Main Results:

  • The HEV 239 vaccine (Hecolin) is the only licensed Hepatitis E vaccine globally.
  • Phase III trials demonstrated HEV 239 vaccine safety and efficacy.
  • Efficacy of three HEV 239 doses remained 86.6% after 10 years.

Conclusions:

  • The HEV 239 vaccine represents a significant advancement in preventing Hepatitis E.
  • Continued research and development are crucial to address remaining challenges in HEV vaccination.
  • Effective vaccines are vital for controlling HEV epidemics and protecting vulnerable populations.